Minimum intake: we recommend 2 months, 30 capsules are enough for about 30 days
When leg muscle mass declines, as can happen on GLP-1 therapy without adequate protein or exercise, insulin sensitivity can paradoxically worsen even as body weight falls
Affected individuals are typically characterised by lipoatrophic diabetes, insulin resistance and hepatic steatosis ( Agonists of the glucagon-like peptide-1 receptor (GLP-1R) deliver significant beneficial effects both in treating type 2 diabetes and obesity ( Reports of the effects of GLP-1R agonists in individuals with inherited lipodystrophies are currently limited to only 3 case studies, and these examine FPLD but not CGL patients ( Here we used a well validated Bscl2 -null (seipin knockout) mouse model of CGL type 2 (CGL2) to examine the effectiveness of a GLP-1R agonist, in treating lipoatrophic diabetes, hepatic steatosis and hyperphagia in CGL to inform the adoption of this class of drugs for individuals with lipodystrophy
Titration and dosing schedules vary from their diabetes indications provided above
Researchers became interested in the combination after observing that glutathione levels tend to decline with age while oxidative stress, inflammation, and mitochondrial dysfunction increase.59 The idea is that providing both cysteine and glycine may help the body rebuild glutathione more efficiently than either nutrient alone
